SubjectWell Offers Registry of Patients Willing to Participate in COVID-19 Research
SubjectWell announced that it has developed a growing patient registry of individuals in the U.S. interested in participating in clinical trials for a COVID-19 vaccine as these trials become more widely available. 10,000 people from SubjectWell’s patient network have already opted into the list, with approximately 70,000 individuals expected to register by the end of May. Researchers will have access to interested individuals who could randomize for various types of trials, whether they are healthy volunteers with no previous exposure to COVID-19, currently sick with the virus, or who have recovered.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
